Showing 1441-1450 of 5771 results for "".
- Bausch + Lomb to Present New Scientific Data and Analyses at American Academy of Ophthalmology Annual Meetinghttps://modernod.com/news/bausch-lomb-to-present-new-scientific-data-and-analyses-at-american-academy-of-ophthalmology-annual-meeting/2481916/Bausch + Lomb announced three podium presentations and seven poster presentations during the American Academy of Ophthalmology (AAO)
- Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophyhttps://modernod.com/news/annexon-receives-prime-designation-from-the-ema-for-anx007-for-the-treatment-of-geographic-atrophy/2481911/Annexon announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to ANX007 for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The EMA granted this designation based on the phase 2 ARCHER
- American Academy of Optometry Announces 2023 New Fellows and Diplomateshttps://modernod.com/news/american-academy-of-optometry-announces-2023-new-fellows-and-diplomates/2481910/The American Academy of Optometry recently hosted Academy 2023 New Orleans from October 11-14, 2023. During the organization’s annual meeting, the Academy welcomed 257 new fellows to its ranks. Along with this strong showing of new fellows, 12 current fellows earned the distinction of
- Aurion Biotech Announces First Subject Dosed in US Phase 1/2 Clinical Trialhttps://modernod.com/news/aurion-biotech-announces-first-subject-dosed-in-us-phase-1-2-clinical-trial/2481908/Aurion Biotech announced that it has dosed the first subject in its phase 1/2 US clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. “On the heels of our recent approval in Japan, we ar
- The Vision Council and RX Announce New Host City for Vision Expo East 2025 and Future Yearshttps://modernod.com/news/the-vision-council-and-rx-announce-new-host-city-for-vision-expo-east-2025-future-years/2481903/The Vision Council and RX, co-owners of Vision Expo, announced that Vision Expo East 2025 will take place in Orlando, Florida at the Orange County Convention Center (OCCC) February 19-22, 2025. Vision Expo East’s final show in New York will occur March 14-17, 2024. Vision Exp
- Pixium Vision Announces the Launch of a Process to Find Buyershttps://modernod.com/news/pixium-vision-announces-the-launch-of-a-process-to-find-buyers/2481900/Pixium Vision SA announced that a tender process (appel d’offres) for the purpose of finding buyers to acquire the company's business will be published October 19. Unable to find financial investors within the restricted timeframe and in line with the company's n
- Haag-Streit Announces Launch of Haag-Streit Japanhttps://modernod.com/news/haag-streit-announces-launch-of-haag-streit-japan/2481899/In a move to solidify its regional presence following recent expansions into China and Singapore, Haag-Streit announced the establishment of Haag-Streit Japan KK. "Our expansion into Japan is a milestone in Haag-Streit’s international commercial expansion plan,
- Staar Surgical Celebrates 30th Anniversary of Implantable Collamer Lens (ICL)https://modernod.com/news/staar-surgical-celebrates-30th-anniversary-of-implantable-collamer-lens-icl/2481892/Staar Surgical is celebrating the 30th anniversary of its proprietary Implantable Collamer Lens (ICL). The first ICLs were implanted by a group of surgeons in October 1993, including Roberto Zaldivar, MD, Founder of the Zaldivar Institute. The early ICLs have evolved into the curre
- Aviceda Announces its Glycomimetic Nanoparticle Candidate AVD-104 Demonstrates Clinical Safety in the Treatment of GAhttps://modernod.com/news/aviceda-announces-its-glycomimetic-nanoparticle-candidate-avd-104-demonstrates-clinical-safety-in-the-treatment-of-ga/2481886/Aviceda Therapeutics announced the recent presentation of positive data about AVD-104, its lead ophthalmic clinical asset, at the Euretina congress held in Amsterdam. The phase 2/3 SIGLEC trial is currently underway evaluating patients with geographic atrophy secondary to age-
- OKYO Pharma Announces Filing of an IND Application for OK-101 to Treat Neuropathic Corneal Painhttps://modernod.com/news/okyo-pharma-announces-filing-of-an-ind-application-for-ok-101-to-treat-neuropathic-corneal-pain/2481882/OKYO Pharma announced that it filed an investigational new drug (IND) application with the FDA for the development of OK-101 to treat Neuropathic Corneal Pain (NCP). Study enrollment is planned to commence during Q1 2024 following IND allowance by the FDA. There is no FDA-appr